Anti-von Willebrand Factor Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the aminoterminal region of von Willebrand factor (VWF), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential
UniProt
P31324
Size
100ug
Cat. #
RP1PKARIIB

In stock

SKU
RP-PKARIIB

Options

As low as: $130.00

Target Overview

von Willebrand factor (VWF, UniProt P04275) is a large secreted glycoprotein essential for primary hemostasis and platelet adhesion at sites of vascular injury. The 2813-amino acid protein functions as a molecular bridge between sub-endothelial collagen and the platelet-surface receptor complex GPIb-IX-V, facilitating platelet tethering under high shear stress conditions. VWF also serves as a critical chaperone for coagulation factor VIII, stabilizing its heterodimeric structure in circulation and protecting it from premature proteolytic degradation. Synthesized primarily in endothelial cells and megakaryocytes, VWF is stored in Weibel-Palade bodies and alpha granules before regulated secretion into plasma and the subendothelial matrix. Multimeric assembly of VWF is crucial for function, with ultra-large multimers exhibiting the highest adhesive capacity. Researchers study VWF in the context of bleeding disorders, thrombotic microangiopathies, cardiovascular disease, and inflammatory conditions where endothelial activation drives pathological hemostasis.

Background

VWF plays a dual role in hemostasis by mediating both platelet adhesion and stabilization of factor VIII. Following vascular injury, VWF binds exposed collagen through its A3 domain while simultaneously engaging platelet GPIb-IX-V via the A1 domain, creating a reversible tether that slows platelets in flowing blood. This interaction is shear-dependent, becoming increasingly important in high-flow arterial vessels where traditional integrin-mediated adhesion is insufficient. The factor VIII-binding region resides in the aminoterminal D'-D3 domains, where VWF shields factor VIII from recognition by clearance receptors and premature inactivation, prolonging its half-life approximately 20-fold. Deficiency or dysfunction of VWF causes von Willebrand disease, the most common inherited bleeding disorder, while elevated VWF levels and altered multimer patterns associate with thrombotic risk, inflammation, and cardiovascular events. Recent studies have expanded understanding of VWF beyond classic coagulation. Ekström et al. (2026) identified VWF as part of a targeted proteomic signature distinguishing vascular phenotypes in type 1 diabetes, reinforcing its role as a marker of endothelial dysfunction. Šantić et al. (2026) demonstrated dysregulated VWF expression contributes to thromboinflammatory activation in inflammatory bowel disease, highlighting cross-talk between hemostatic and immune pathways. VWF multimer analysis, ristocetin cofactor activity assays, and antigen quantification remain standard diagnostic approaches, while advanced proteomics and genetic studies continue to reveal nuanced regulatory mechanisms governing its synthesis, secretion, and proteolytic processing by ADAMTS13.

References

  1. Ekström O et al (2026) Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study. Cardiovasc Diabetol. PubMed · DOI
  2. Šantić R et al (2026) Molecular determinants of thromboinflammatory activation in inflammatory bowel disease. J Mol Med (Berl). PubMed · DOI
  3. Li Y et al (2026) Association Between Hemostatic Profiles and Hypertensive Disorders of Pregnancy: A Multi-Omics Mendelian Randomization Study. Int J Womens Health. PubMed · DOI
  4. Budnik A et al (2026) Cardiovascular peptide markers are associated with age-related macular degeneration in the Bialystok PLUS general population cohort. Sci Rep. PubMed · DOI
  5. Sucker C et al (2026) The Impact of Human ABO Blood Groups on Thrombin Generation in Platelet-Poor Plasma. Clin Lab. PubMed · DOI

Additional Specifications

Gene Symbol VWF
UniProt ID P31324
Host Species Rabbit
Species Reactivity Validated- Human
Potential
Pack Size 100ug
Immunogen Immunogen is proprietary and confidential. Immunogen generated in amino acid region 1-51.
Alternate Names VWF, von Willebrand antigen, F8VWF

Frequently Asked Questions

What is the expected molecular weight for PKA-RIIB on Western blot?

PKA-RIIB (also known as PRKAR2B) typically migrates at approximately 46 kDa on reducing SDS-PAGE, corresponding to the full-length regulatory subunit. Some labs report doublets or minor bands near 50 kDa depending on post-translational modifications or splice variants. Human tissue lysates from brain, adipose, or adrenal gland usually show the cleanest signal, as RIIB is highly expressed in these tissues. If you see additional bands, verify lysate quality and consider phosphatase treatment to collapse phosphorylated species. Starting dilution of 1:1000 works for most enriched samples.

How does PKA-RIIB differ from PKA-RIα and other regulatory subunit isoforms?

PKA-RIIB is one of four mammalian regulatory subunits (RIα, RIβ, RIIα, RIIB) that determine cAMP sensitivity and subcellular localization of protein kinase A holoenzymes. RIIB exhibits higher cAMP affinity than type I subunits and contains an N-terminal domain that mediates association with A-kinase anchoring proteins, directing compartmentalized signaling. Tissue distribution also differs: RIIB is abundant in brain, adipose, and endocrine tissues, whereas RIα is more ubiquitous. Antibody cross-reactivity between isoforms is common, so include isoform-specific controls or knockdown lysates if selectivity is critical to your experiment.

Does this PKA-RIIB antibody cross-react with mouse or rat samples?

This antibody is validated for human PKA-RIIB. Cross-reactivity with mouse and rat is predicted based on high sequence homology in the immunogen region, but we have not formally validated it in rodent lysates. If you plan to use mouse or rat samples, run a pilot blot with brain or adipose lysate alongside a human positive control. Many researchers report successful detection in rodent tissues at the recommended 1:1000 dilution, but band intensity and specificity should be confirmed in your hands before committing to a full experiment.

What sample preparation is recommended for detecting PKA-RIIB by Western blot?

Use RIPA or a Triton X-100-based lysis buffer supplemented with protease and phosphatase inhibitors, as PKA-RIIB is a cytosolic and membrane-associated protein. Load 20–40 µg total protein per lane for whole-cell lysates; enriched fractions or tissues with high RIIB expression may require less. Avoid boiling samples excessively, as prolonged heating can cause aggregation of some regulatory subunits. Include a human brain or adipose tissue lysate as a positive control. If signal is weak, verify antibody dilution, increase exposure time, or consider enriching the cytosolic fraction by differential centrifugation.

What controls should I include when using this PKA-RIIB antibody?

Include a known RIIB-expressing tissue or cell line as a positive control—human brain lysate, differentiated adipocytes, or adrenal gland work well. A negative control could be a tissue with low or absent RIIB expression, though complete absence is rare. For specificity, consider siRNA or shRNA knockdown of PRKAR2B in your cell model; loss of the 46 kDa band confirms on-target binding. A no-primary-antibody control helps rule out non-specific secondary binding. If you suspect isoform cross-reactivity, run lysates from cells overexpressing individual PKA-R isoforms in parallel.

Can I use this antibody for immunofluorescence or immunohistochemistry on PKA-RIIB?

Triple Point Biologics antibodies are validated for Western blot and immunohistochemistry applications. This rabbit polyclonal should be compatible with IHC on formalin-fixed paraffin-embedded sections, though you will need to optimize antigen retrieval and blocking conditions for your tissue type. For immunofluorescence, start with a 1:100 to 1:200 dilution and include a peptide-competition control or RIIB-knockdown cells to confirm specificity. Cytosolic and perinuclear staining patterns are typical for RIIB. We recommend piloting a small batch before scaling up, as fixation and permeabilization can influence epitope accessibility.

How should I store the PKA-RIIB antibody and how long does it remain stable?

Store the antibody at –20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. Once thawed, an aliquot can be kept at 4°C for up to one month if supplemented with 0.02–0.05% sodium azide or a commercial stabilizer. Do not store diluted antibody for extended periods; prepare working dilutions fresh in blocking buffer for each experiment. Under proper storage, the antibody typically retains activity for at least two years from the date of manufacture. If you notice declining signal or increased background over time, prepare a fresh aliquot.

Validation imagery coming soon

Western blot validation figures for RP-PKARIIB will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

Also known as:

  • VWF
  • von Willebrand antigen
  • F8VWF
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →